OS Therapies Inc. has announced the successful completion of a warrant exercise inducement and exchange offer with nine accredited investors, raising $7.53 million in gross proceeds. All nine investors holding existing warrants agreed to exercise or pre-fund their warrants for cash. The funds will extend the company’s capital runway into 2027 and will be used to support regulatory filings and commercial preparations for OST-HER2 in metastatic osteosarcoma, as well as preparations for the proposed spinoff of its subsidiary, OS Animal Health.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 280045) on January 12, 2026, and is solely responsible for the information contained therein.